Concentra Group Holdings Parent, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CON in the last 30 days.
See all $CON insider activity →Pacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
Concentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE September 8, 2026 Concentra Appoints Tanner Newton Chief Financial Officer Experienced Concentra leader brings deep knowledge of the company’s strategy, financial operations and investor community DALLAS--Concentra® (NYSE: CON), the
S&P Global Ratings upgraded Concentra Group Holdings (NYSE:CON) to BB from BB-, citing lower leverage and strong performance. The company's adjusted leverage fell below 3.5x in Q2, with projections improving to 3x by fiscal 2027. Concentra generated $250M in annual free operating cash flow and increased EBITDA by over $100M since fiscal 2024, driven by growth and cost controls. S&P maintained a stable outlook but noted potential downgrade risks.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CON (Concentra Group Holdings Parent, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CON coverage spans earnings, market movers and corporate actions.
Bullish on strong revenue growth and outlook.
The CFO appointment signals continuity in financial strategy and may support investor confidence, but immediate price impact is expected to be modest.
Rating upgrade improves credit perception and may lower borrowing costs, supporting upside potential.
The buyback reduces float and signals confidence, likely providing modest upward pressure on CON.
The insider sale may signal modest concern, but the size is not material for the market.
AlphAI scores every news story that mentions CON with an AI model for sentiment and relevance, and aggregates insider trades from Concentra Group Holdings Parent, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
2 min readConcentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE September 8, 2026 Concentra Appoints Tanner Newton Chief Financial Officer Experienced Concentra leader brings deep knowledge of the company’s strategy, financial operations and investor community DALLAS--Concentra® (NYSE: CON), the
2 min readS&P Global Ratings upgraded Concentra Group Holdings (NYSE:CON) to BB from BB-, citing lower leverage and strong performance. The company's adjusted leverage fell below 3.5x in Q2, with projections improving to 3x by fiscal 2027. Concentra generated $250M in annual free operating cash flow and increased EBITDA by over $100M since fiscal 2024, driven by growth and cost controls. S&P maintained a stable outlook but noted potential downgrade risks.
1 min readConcentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Stock Repurchase Agreement On August 21, 2026, Concentra Group Holdings Parent, Inc. (the “Company”) entered into a stock repurchase agreement (the “Stock Repurchase Agreement”) with Robert A. Ortenzio, chairman of the Company
2 min readORTENZIO ROBERT A sold (to issuer) 230,000 indirectly-held shares of Concentra Group Holdings Parent, Inc. (CON) at an average of $34.78 ($34.65–$35.65, $8.00M total) across 4 trades on 2026-08-21.
1 min readORTENZIO ROBERT A sold (to issuer) 770,000 shares of Concentra Group Holdings Parent, Inc. (CON) at $34.65 ($26.68M total) on 2026-08-21.
1 min readBiotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.
4 min readConcentra Group Holdings Parent (CON) reported Q2 2026 revenue of $606 million (+10% YoY) and adjusted EBITDA of $140.9 million (+22.5%), with adjusted EPS of $0.52. Management raised full-year guidance: revenue to $2.325B-$2.375B and adjusted EBITDA to $485M-$495M. Net leverage fell to 2.99x. A CEO transition to Matt DiCanio takes effect Nov. 1, 2026.
6 min readConcentra Group Holdings Parent (CON) shares rose about 11.5% to around $34 after its Q2 results. Revenue was $606.0m and adjusted EBITDA was $140.9m, implying a 23.3% margin versus about 20.9% a year earlier. Adjusted EPS was $0.52 and free cash flow was $121.0m, nearly double last year.
4 min readConcentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE FOR IMMEDIATE RELEASE Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance Matt DiCanio to become president and CEO and Keith Newton to transition to executive chairman, effective Nov. 1, 2026
6 min read
